Cigna Corporation (CI) Stock Competitors & Peer Comparison
See (CI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CI | $285.38 | +0.55% | 74.5B | 9.11 | $30.90 | +2.18% |
| UNH | $422.45 | -0.22% | 387B | 26.08 | $16.34 | +2.08% |
| CVS | $107.93 | +1.34% | 137.1B | 15.20 | $7.07 | +2.48% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.42% |
| ELV | $383.50 | +2.86% | 80.9B | 12.69 | $29.39 | +1.85% |
| HUM | $401.93 | -1.44% | 46.4B | 24.38 | $15.86 | +0.89% |
| CNC | $66.38 | +3.89% | 32.8B | 26.36 | $2.52 | N/A |
| MOH | $227.32 | +1.11% | 11.7B | 32.57 | $6.92 | N/A |
| OSCR | $29.64 | +2.70% | 7.5B | -49.28 | -$0.59 | N/A |
| ALHC | $20.92 | +4.44% | 4.3B | 228.89 | $0.09 | N/A |
Stock Comparison
CI vs UNH Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, UNH has a market cap of 387B. Regarding current trading prices, CI is priced at $285.38, while UNH trades at $422.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas UNH's P/E ratio is 26.08. In terms of profitability, CI's ROE is +0.15%, compared to UNH's ROE of +0.12%. Regarding short-term risk, CI is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check UNH's competition here
CI vs CVS Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, CVS has a market cap of 137.1B. Regarding current trading prices, CI is priced at $285.38, while CVS trades at $107.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas CVS's P/E ratio is 15.20. In terms of profitability, CI's ROE is +0.15%, compared to CVS's ROE of +0.04%. Regarding short-term risk, CI is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check CVS's competition here
CI vs ANTM Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CI is priced at $285.38, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CI's ROE is +0.15%, compared to ANTM's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ANTM's competition here
CI vs ELV Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, ELV has a market cap of 80.9B. Regarding current trading prices, CI is priced at $285.38, while ELV trades at $383.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas ELV's P/E ratio is 12.69. In terms of profitability, CI's ROE is +0.15%, compared to ELV's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ELV's competition here
CI vs HUM Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, HUM has a market cap of 46.4B. Regarding current trading prices, CI is priced at $285.38, while HUM trades at $401.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas HUM's P/E ratio is 24.38. In terms of profitability, CI's ROE is +0.15%, compared to HUM's ROE of +0.06%. Regarding short-term risk, CI is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check HUM's competition here
CI vs CNC Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, CNC has a market cap of 32.8B. Regarding current trading prices, CI is priced at $285.38, while CNC trades at $66.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas CNC's P/E ratio is 26.36. In terms of profitability, CI's ROE is +0.15%, compared to CNC's ROE of -0.29%. Regarding short-term risk, CI is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check CNC's competition here
CI vs MOH Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, MOH has a market cap of 11.7B. Regarding current trading prices, CI is priced at $285.38, while MOH trades at $227.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas MOH's P/E ratio is 32.57. In terms of profitability, CI's ROE is +0.15%, compared to MOH's ROE of +0.04%. Regarding short-term risk, CI is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MOH's competition here
CI vs OSCR Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, OSCR has a market cap of 7.5B. Regarding current trading prices, CI is priced at $285.38, while OSCR trades at $29.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas OSCR's P/E ratio is -49.28. In terms of profitability, CI's ROE is +0.15%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, CI is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check OSCR's competition here
CI vs ALHC Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, ALHC has a market cap of 4.3B. Regarding current trading prices, CI is priced at $285.38, while ALHC trades at $20.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas ALHC's P/E ratio is 228.89. In terms of profitability, CI's ROE is +0.15%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ALHC's competition here
CI vs CLOV Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, CLOV has a market cap of 2.4B. Regarding current trading prices, CI is priced at $285.38, while CLOV trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas CLOV's P/E ratio is -38.50. In terms of profitability, CI's ROE is +0.15%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, CI is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CLOV's competition here
CI vs BHG Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CI is priced at $285.38, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas BHG's P/E ratio is -0.12. In terms of profitability, CI's ROE is +0.15%, compared to BHG's ROE of +0.04%. Regarding short-term risk, CI is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BHG's competition here
CI vs CABR Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, CABR has a market cap of 19.2M. Regarding current trading prices, CI is priced at $285.38, while CABR trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas CABR's P/E ratio is -2.32. In terms of profitability, CI's ROE is +0.15%, compared to CABR's ROE of -3.28%. Regarding short-term risk, CI is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CABR's competition here
CI vs UAM Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CI is priced at $285.38, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas UAM's P/E ratio is 1.01. In terms of profitability, CI's ROE is +0.15%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CI is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check UAM's competition here
CI vs GTS Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CI is priced at $285.38, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas GTS's P/E ratio is 10.41. In terms of profitability, CI's ROE is +0.15%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CI is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check GTS's competition here
CI vs AET Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, AET has a market cap of 0. Regarding current trading prices, CI is priced at $285.38, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas AET's P/E ratio is 9.57. In terms of profitability, CI's ROE is +0.15%, compared to AET's ROE of +0.11%. Regarding short-term risk, CI is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check AET's competition here
CI vs MGLN Comparison July 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.5B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CI is priced at $285.38, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 9.11, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CI's ROE is +0.15%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CI is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MGLN's competition here